Riskpilot← Back to searchSign inGet full accessORIFARM AS
ASActiveOrg 979996233Sandakerveien 138, 0484 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 199819 employees
Revenue 2024
NOK 370,7M
-8% vs 2023
EBITDA margin
2.2%
0% vs 2023
Equity ratio
21.1%
Financial strength
Net profit 2024
NOK 4,9M
+25% vs 2023
| Revenue | NOK 370,7M | -8% |
| EBITDA | NOK 8,3M | +0% |
| Net profit | NOK 4,9M | +25% |
| Total assets | NOK 60,9M | -74% |
| Equity | NOK 12,9M | -47% |
| Employees | 19 | — |
Legal name
ORIFARM AS
Org number
979996233
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
24. juni 1998
Share capital
NOK 500 000
Employees
19 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og ett styremedlem i fellesskap eller to styremedlemmer i fellesskap.
Address
Sandakerveien 138, 0484 Oslo
Phone
+4721696910
Email
info@orifarm.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238 963 | 210 896 | 184 825 | 202 280 | 276 071 | 246 014 | 207 998 | 257 865 | 396 487 | 452 306 | 402 243 | 370 697 |
| Staff expenses | −2 291 | −2 765 | −2 564 | −2 735 | −3 377 | −3 812 | −4 601 | −4 693 | −4 415 | −5 629 | −2 309 | −5 611 |
| EBITDA | 5 110 | 3 971 | 2 535 | 2 164 | 3 470 | 4 162 | 4 213 | 6 977 | 8 127 | 8 808 | 8 308 | 8 307 |
| Depreciation & amort. | −1 933 | −2 076 | −1 028 | −1 560 | −2 250 | −2 693 | −2 921 | −4 669 | −4 559 | −4 285 | −4 237 | −3 674 |
| EBIT | 3 177 | 1 895 | 1 507 | 605 | 1 220 | 1 469 | 1 292 | 2 308 | 3 568 | 4 523 | 4 072 | 4 634 |
| Net financials | −797 | −773 | −398 | −409 | −469 | −287 | −297 | 1 038 | −975 | −927 | 1 062 | 1 778 |
| Profit before tax | 2 380 | 1 122 | 1 109 | 196 | 751 | 1 183 | 995 | 3 347 | 2 593 | 3 596 | 5 134 | 6 412 |
| Tax | 670 | 325 | 333 | 89 | 209 | 315 | 257 | 832 | 638 | 856 | 1 202 | 1 505 |
| Net profit | 1 710 | 797 | 776 | 106 | 542 | 868 | 738 | 2 515 | 1 956 | 2 739 | 3 932 | 4 907 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 66 847 | 45 996 | 37 284 | 81 328 | 78 595 | 86 624 | 56 943 | 66 075 | 97 629 | 100 340 | 231 671 | 60 920 |
| Equity | 11 383 | 12 180 | 12 956 | 13 062 | 13 604 | 14 472 | 15 635 | 18 150 | 20 105 | 20 344 | 24 276 | 12 883 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 317 | 862 | 983 | 981 | 914 | 788 |
| Short-term debt | 55 465 | 33 816 | 24 329 | 68 266 | 64 991 | 72 152 | 40 991 | 47 063 | 76 541 | 79 014 | 206 481 | 47 249 |
| Total debt | 55 465 | 33 816 | 24 329 | 68 266 | 64 991 | 72 152 | 41 308 | 47 926 | 77 524 | 79 995 | 207 395 | 48 036 |
EBITDA margin
2.2%
This company
15.8%
Market median
-86% vs market
20132024
Equity ratio
21.1%
This company
38.2%
Market median
-45% vs market
20132024
Return on equity
38.1%
This company
18.4%
Market median
+107% vs market
20132024
Net profit margin
1.3%
This company
8.1%
Market median
-84% vs market
20132024
Asset turnover
6.09×
This company
1.12×
Market median
+444% vs market
20132024
Debt / equity
3.73×
This company
0.62×
Market median
-502% vs market
20132024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SH Chief Executive Officer | Chief Executive Officer | 2007 | — | — |
BB Deputy Member | Deputy Member | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Orfarm Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ORIFARM AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sverre Haugen | Chief Executive Officer | 0 companies |
| Birgitte Bøgh-Sørensen | Deputy Member | 0 companies |
| Erik Sandberg | Chairman | 0 companies |
| Mads Fink Eriksen | Board of Directors | 0 companies |
| Jens Peter Nielsen | Board of Directors | 0 companies |
| Hans Carl Bøgh-Sørensen | Chairman | 0 companies |